How much funding has Carmot Therapeutics raised?

Carmot Therapeutics has raised $497.0M in total funding, most recently a Series E round.

Who are Carmot Therapeutics's investors?

Carmot Therapeutics's investors include Deep Track Capital, The Column Group, Horizons Ventures, Roche, Franklin Templeton, Amgen.

When was Carmot Therapeutics founded?

Carmot Therapeutics was founded in 2008.

Where is Carmot Therapeutics headquartered?

Carmot Therapeutics is headquartered in Berkeley, California, United States.

What industry is Carmot Therapeutics in?

Carmot Therapeutics operates in Biotech, Therapeutics.

How many employees does Carmot Therapeutics have?

Carmot Therapeutics has 11-50 employees.

Carmot Therapeutics

Acquired

Developing life-changing therapeutics for metabolic disease

Berkeley, United States · Founded 2008 · $497.0M raised

Biotech

Therapeutics

Headquarters: Berkeley, California
Employees: 11–50
Founded: 2008
Business Model: biotech

Website: carmottherapeutics.com
Total Funding: $497.0M
Last Round: $150.0M Series EMay 2023
Rounds: 5

About

Carmot Therapeutics was a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and type 2 diabetes. The company's pipeline included CT-388 (a once-weekly injectable dual GLP-1/GIP receptor agonist), CT-868 (dual GLP-1/GIP receptor agonist in Phase 2 for obesity/T1D), and CT-996 (an oral small molecule GLP-1 receptor agonist). Carmot's drug candidates were designed as biased agonists that activate cAMP signaling with minimal beta-arrestin recruitment, expected to yield prolonged pharmacological activity and strong tolerability. The company was acquired by Roche in January 2024 for $2.7 billion upfront ($3.1 billion total) and is now operated as part of Roche/Genentech's obesity and diabetes pipeline.

Summary

Carmot Therapeutics is a Biotech company based in Berkeley, United States, founded in 2008. It has raised $497.0M in total across 5 rounds, most recently a $150.0M Series E round in May 2023. Investors include Deep Track Capital, The Column Group and Horizons Ventures.

LinkedIn X (Twitter)